New Data Reveals Continued Meningitis B Threat Among Students

Young adults, especially those attending university, remain particularly vulnerable to meningococcal meningitis and septicaemia. Recent statistics from the UK Health Security Agency (UKHSA) reveal that Meningitis B (MenB) accounted for 97% of invasive meningococcal disease cases in individuals aged 15 to 24 in England during the period from 2025 to 2026, comprising 93 out of 96 cases.

Protective Measures for Freshers

In light of these figures, UKHSA is urging first-year students to ensure they receive both doses of the MenB vaccine prior to the commencement of the academic term. This precaution is crucial, as students entering their first year face a meningococcal disease risk that is approximately seven times greater than those of the same age who are not attending university.

The newly released data, featured in the Invasive Meningococcal Disease (IMD) report for England, also indicates that MenB was the predominant cause of the disease among nearly all age groups under 25, including infants, where it represented 92% of cases, and 1 to 4-year-olds, with a concerning 100% of cases attributed to MenB.

Today’s figures for younger children underscore the necessity for parents to ensure their infants receive all three scheduled MenB vaccines as part of the routine Childhood Programme. Timely vaccination is the most effective defence against MenB during the early years of life when children are particularly susceptible to infection.

Impact of Recent Outbreaks

Invasive Meningococcal Disease can have severe consequences, as evidenced by 26 fatalities recorded among the total of 348 confirmed IMD cases over the year. A notable outbreak of Meningitis B occurred in March 2026 in Kent, linked to 21 cases among students and young people in the Canterbury area. This was followed by two additional MenB outbreaks, both involving three or more cases in Dorset and Berkshire, tragically resulting in three deaths. Some survivors are now contending with long-term health implications.

In response to these outbreaks, a one-off MenB vaccination programme was initiated this summer, aimed at those at the highest immediate risk of MenB disease, particularly school leavers and first-year university students.

Current Vaccination Statistics

As of 31 August 2026, the NHS has administered 246,089 doses of the MenB vaccine to young people; however, thousands of school leavers and first-year undergraduates remain eligible for vaccination ahead of freshers’ week. With the onset of freshers’ week across the nation, students will be in close contact with numerous new individuals in halls, social gatherings, and shared accommodation, thereby increasing the likelihood of exposure to the meningococcal bacteria.

All eligible students are strongly encouraged to come forward for both doses of the MenB vaccine as soon as possible and to familiarise themselves with the signs and symptoms of meningitis to better protect themselves and their peers.

Expert Insights on Vaccination

Dr Shamez Ladhani, a Consultant Epidemiologist at UKHSA, remarked, “While university is an exciting chapter, it is also a time when young people face heightened risk of meningococcal disease due to prolonged close contact with many new individuals. Today’s figures highlight the very real nature of that risk.”

Dr Ladhani further emphasised the importance of the routine childhood MenB vaccine in safeguarding infants, urging parents to ensure their children receive all three doses as scheduled. He stated, “It is absolutely vital that everyone eligible receives their two doses, ideally before term begins or as soon as possible. Two doses are crucial for comprehensive protection against most strains of Meningitis B, so please do not delay.”

Call to Action from Health Officials

Dame Diana Johnson, Minister of State for Public Health and Patient Safety, expressed her satisfaction that nearly 250,000 young people have received their MenB jab before heading to university this month, commending the NHS staff and pharmacies nationwide for their efforts. However, she acknowledged that more work is needed to ensure every eligible young person takes action to protect themselves from this serious disease.

Vinny Smith, Chief Executive of the Meningitis Research Foundation, reinforced the urgency for every eligible young person in England to accept the limited-time MenB vaccine offer now available through the NHS. He stated, “This year’s MenB vaccination programme is a critical step towards closing the protection gap for teenagers and young adults, an age group where we continue to witness too many cases.”

Understanding the Symptoms of Meningitis

Dr Tom Nutt, Chief Executive of Meningitis Now, stressed the ongoing threat of meningitis to young people, noting that MenB accounted for 97% of cases among 15 to 24-year-olds in England last year. He cautioned against underestimating the risks associated with the disease, which can manifest suddenly and lead to life-altering consequences. He urged eligible individuals to get vaccinated, as two doses could provide vital protection.

While the MenB vaccine offers protection against most strains, it does not cover all infections that can lead to meningitis and septicaemia. It is essential for everyone to recognise the symptoms of meningitis and septicaemia and to seek medical advice immediately, as early detection and treatment can be lifesaving.

Symptoms may manifest in any order and include:

• High temperature
• Cold hands and feet
• Vomiting
• Confusion
• Rapid breathing
• Muscle and joint pain
• Pale, mottled or blotchy skin (which may be less visible on darker skin)
• Spots or a rash (which may be less visible on darker skin)
• Headache
• Stiff neck
• Discomfort in bright lights
• Excessive sleepiness or difficulty waking
• Seizures

Additional Vaccination Recommendations

Beyond MenB, meningococcal types A, C, W, and Y are also responsible for meningitis and septicaemia in young people. The MenACWY vaccine is routinely offered to teenagers as part of the school immunisation programme. All teenagers are eligible for MenACWY vaccination until their 25th birthday, and it is critical to seize this opportunity if they have not been vaccinated in school, particularly when entering higher education institutions where the risk of disease is significantly heightened.

For further information on meningococcal disease, visit the NHS’s resources on the MenB vaccine for children, or for students looking to book or verify eligibility for a vaccine, see the NHS page for MenB vaccination appointments. Additional advice and support can be found at Meningitis in Students – Information and Advice.